William Blair & Company
LCTX icon

William Blair & Company’s Lineage Cell Therapeutics LCTX Stock Holding History

William Blair & Company’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-20,000
Closed -$18.1K – 1884
2025
Q2 		$18.1K Buy
+20,000
New +$11.9K ﹤0.01% 1686

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

William Blair & Company's LCTX Position: Q3 2025 in Review

William Blair & Company sold out of Lineage Cell Therapeutics (LCTX) in Q3 2025, closing a stake of 20,000 shares — an estimated $18.1K sold.

William Blair & Company first reported a position in LCTX in Q2 2025 and held it in 1 quarter. The position peaked at $18.1K in Q2 2025. 112 funds tracked by Wall St. Rank hold LCTX as of Q3 2025.

  • William Blair & Company reported no remaining Lineage Cell Therapeutics position as of Q3 2025 after selling out during the quarter.
  • William Blair & Company sold 20,000 Lineage Cell Therapeutics shares in Q3 2025, an estimated $18.1K.
  • William Blair & Company first reported a position in Lineage Cell Therapeutics in Q2 2025 and held it in 1 quarter.
  • William Blair & Company's Lineage Cell Therapeutics position peaked at $18.1K in Q2 2025.
  • 112 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2025.

Based on William Blair & Company's 13F filing for Q3 2025, filed 12 Nov 2025.